All Industries

Top Biotech Companies

5,081 Biotech companies, sorted by total funding raised.

Beam TherapeuticsIPO

Biotechnology company developing precision genetic medicines through proprietary base editing tec...

Cambridge, United States201–500Biotech, Gene Editing
Growth Equity·$528.0M·Feb 2026
ApellisIPO

Global biopharmaceutical company developing targeted C3 therapies to treat diseases driven by exc...

Waltham, United States501–1000Biotech, Healthcare
Corporate Round·$522.6M·Feb 2023
Relay TherapeuticsIPO

Clinical-stage precision medicines company using protein-motion-driven drug discovery to design s...

Cambridge, United States51–200Biotech, Drug Discovery
Series C·$520.0M·Dec 2018
Angitia Biopharmaceuticals

Clinical-stage biotech developing novel bispecific antibody therapies for musculoskeletal and bon...

Westlake Village, United States51–200Biotech, Healthcare
Series D·$506.0M·Feb 2026
MetseraAcquired

Clinical-stage biopharmaceutical company developing next-generation oral and injectable medicines...

New York, United States11–50Biotech, Obesity
Series B·$505.0M·Nov 2024
ADC Therapeutics SA Common SharesIPO

Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.

Lausanne, Switzerland201–500Biotech, Healthcare
Series E·$501.0M·Jun 2019
Summit Therapeutics Inc.IPO

Biopharmaceutical oncology company focused on discovery, development, and commercialization of ca...

Miami, United States51–200Biotech, Healthcare
Corporate Round·$500.0M·Oct 2025
RecursionIPO

AI-powered drug discovery and development company that uses biological and chemical datasets, mac...

Salt Lake City, United States501–1000Artificial Intelligence, Biotech
Corporate Round·$497.9M·Jul 2023
Carmot TherapeuticsAcquired

Carmot Therapeutics was a clinical-stage biotech developing GLP-1-based therapeutics for obesity ...

Berkeley, United States11–50Biotech, Therapeutics
Series E·$497.0M·May 2023
RAPT TherapeuticsIPO

Clinical-stage biopharmaceutical developing immune-targeting therapeutics for inflammatory and im...

San Francisco, United States51–200Biotech, Healthcare
Private Equity·$497.0M·Oct 2025
Biohaven Ltd. Common SharesIPO

Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...

New Haven, United States201–500Biotech, Healthcare
Venture Round·$493.6M·Aug 2020
GenentechIPO

Biotechnology company that discovers and develops medicines for serious, life-threatening disease...

San Francisco, United States10001+Biotech, Drug Discovery
Corporate Round·$492.3M·Feb 1990
LarondeClosed

Endless RNA therapeutics for durable protein expression

Cambridge, United States11–50Biotech, Healthcare
Series B·$490.0M·Aug 2021
Piramal Pharma

India-based pharmaceutical company offering CDMO services, critical care products, and consumer h...

Mumbai, India10001+Biotech, Healthcare
Corporate Round·$490.0M·Jun 2020
Kallyope

Kallyope leverages unique insights into neural signaling pathways to develop innovative medicines...

New York, United States51–200Biotech, Drug Discovery
Grant·$487.2M·May 2023
Innovent BiologicsIPO

Developing and commercializing high-quality biologic medicines.

Suzhou, China5001–10000Biotech, Healthcare
Venture Round·$475.0M·Jan 2025
Athelas

Digital tools for healthcare providers

Mountain View, United States51–200Biotech, Healthcare
Venture Round·$474.0M·May 2026
SynthegoAcquired

Provides CRISPR reagents, engineered nucleases, and GMP manufacturing to researchers and therapeu...

Redwood City, United States51–200Biotech, Genomics
Series E·$468.6M·Feb 2022
Pathos

Pathos is an AI-enabled biotechnology company focused on re-engineering drug development.

Chicago, United States51–200Artificial Intelligence, Biotech
Series D·$467.0M·May 2025
DNA Script

DNA Script develops the SYNTAX platform for enzymatic DNA synthesis, enabling labs to print high-...

Paris, France51–200Biotech, Synthetic Biology
Series C·$466.5M·Jan 2022
InvivydIPO

Biotechnology company developing antibody-based therapies against evolving viral threats includin...

Waltham, United States51–200Biotech, Healthcare
Series C·$466.0M·Apr 2021
ArvinasIPO

Clinical-stage biotechnology company developing PROTAC protein degraders for oncology and neurode...

New Haven, United States201–500Biotech, Healthcare
Private Equity·$464.9M·Nov 2023
BiofourmisAcquired

AI-driven platform delivering remote patient monitoring and in-home care for health systems, paye...

Boston, United States201–500Artificial Intelligence, Digital Health
Series D·$461.5M·Jul 2022
Nektar TherapeuticsIPO

Research-based development stage biopharmaceutical company that discovers and develops innovative...

San Francisco, United States51–200Biotech, Healthcare
Corporate Round·$460.0M·Feb 2026
ImmunomedicsAcquired

Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...

Morris Plains, United States201–500Biotechnology, Oncology
Private Equity·$459.0M·May 2020